A pan-cancer study identified 56 local cellular programs and 13 spatial niches across 12 cancer types. Multiple niches were linked to prognosis, immunotherapy response, and macrophage spatial distribution.
Researchers have developed an inhalable nanoparticle system for delivering rifampin directly to the lungs, potentially reducing tuberculosis treatment from daily to once-weekly dosing while lowering side effects and improving drug effectiveness.
Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.
Sanofi's oral BTK inhibitor rilzabrutinib received orphan drug designation in Japan for IgG4-related disease and warm autoimmune hemolytic anemia, while also securing U.S. FDA breakthrough therapy designation for the rare anemia indication.
Researchers at Stanford and Harvard are developing nasal spray vaccines offering broad protection against respiratory infections, with early animal and phase 1 human trials showing safety and potential efficacy.
Researchers report advances in cancer treatment through three distinct approaches: repurposing a heart medication to target lymphoma enzymes, blocking stress proteins to enhance immunotherapy, and developing antibodies that restore immune system attacks on tumors.
Researchers discovered that lipocalin 2 (LCN2), a protein released by stressed cancer cells, helps lung and pancreatic tumors evade the immune system by manipulating macrophages and blocking T cell infiltration.
